Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | F2 | P00734 | 1/20 | 0.85 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivaroxaban SCHEMBL77766 | 0.92 | F10 (1.00) | F10ABCB11F2ST14CYP1A2 | |
| Rivaroxaban SCHEMBL3914 | 0.92 | F10 (1.00) | F10ABCB11F2ST14CYP1A2 | |
| Rivaroxaban SCHEMBL7721848 | 0.92 | F10 (1.00) | F10ABCB11F2ST14CYP1A2 | |
| Rivaroxaban SCHEMBL14796329 | 0.91 | F10 (0.98) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL3375861 | 0.90 | F10 (0.86) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL5478295 | 0.89 | F10 (0.85) | F10ABCB11F2ST14CYP1A2 | |
| Rivaroxaban SCHEMBL14796410 | 0.87 | F10 (0.90) | F10ABCB11F2ST14CYP1A2 | |
| Rivaroxaban SCHEMBL30893049 | 0.86 | F10 (0.90) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL13722056 | 0.86 | F10 (0.80) | F10ABCB11F2ST14 | |
| SCHEMBL21305662 | 0.86 | F10 (0.80) | F10ABCB11F2ST14CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013121436-A2 | A PROCESS FOR PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | MEGAFINE PHARMA (P) LTD (IN) | 2013-08-22 | — | — | WO | disclosed |
| EP-1874764-B1 | IMINO-OXAZOLIDINES AND USE THEREOF AS ANTICOAGULANTS | BAYER SCHERING PHARMA AG (DE) | 2010-11-10 | — | — | EP | disclosed |